MedTrace Logo

A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT06444009 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2024-12-02

No results posted yet for this study

Summary

A Randomized, Phase II Study of ivonescimab or cadonilimab or penpulimab in Combination With Cisplatin and Nab-paclitaxel in Patients With locally advanced head and neck squamous cell carcinoma (HNSCC) eligible for resection.

This proposed study will evaluate the efficacy and safety of preoperative administration of ivonescimab or cadonilimab or penpulimab combined with chemotherapy in HNSCC who are eligible for resection.

Conditions

Interventions

DRUG

Ivonescimab combined with TP

Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.

DRUG

Cadonilimab combined with TP

Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.

DRUG

Penpulimab combined with TP

Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.

Sponsors & Collaborators

  • Lei Liu

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2025-12-01
Completion
2027-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06444009 on ClinicalTrials.gov